Modelling the Cost Effectiveness of Disease-Modifying Treatments for Multiple Sclerosis Joel P. ThompsonAmir AbdolahiKatia Noyes Practical Application 03 May 2013 Pages: 455 - 469
Trabectedin for the Treatment of Advanced Metastatic Soft Tissue Sarcoma: A NICE Single Technology Appraisal Rachid RafiaEmma SimpsonDiana Papaioannou Review Article 09 April 2013 Pages: 471 - 478
Cabazitaxel for the Second-Line Treatment of Metastatic Hormone-Refractory Prostate Cancer: A NICE Single Technology Appraisal Ben KearnsMyfanwy Lloyd JonesChris Littlewood Review Article 12 April 2013 Pages: 479 - 488
Disutility of Illness for Caregivers and Families: A Systematic Review of the Literature Eve WittenbergLisa A. Prosser Systematic Review 10 April 2013 Pages: 489 - 500
Transferability of Indirect Cost of Chronic Disease: A Systematic Review and Meta-Analysis Fei-Li ZhaoFeng XieShu-Chuen Li Systematic Review 26 April 2013 Pages: 501 - 508
Simulating Lifetime Outcomes Associated with Complications for People with Type 1 Diabetes Tom W. C. LungPhilip M. ClarkeAndrew Farmer Original Research Article 13 April 2013 Pages: 509 - 518
Cost Effectiveness of Targeted High-dose Atorvastatin Therapy Following Genotype Testing in Patients with Acute Coronary Syndrome Anju ParthanKevin J. LeahyMilton C. Weinstein Original Research Article 13 April 2013 Pages: 519 - 531
A Comment on Craig et al.: ‘‘Retigabine for the Adjunctive Treatment of Adults with Partial-Onset Seizures in Epilepsy with and without Secondary Generalization: A NICE Single Technology Appraisal’’ Przemysław HolkoPaweł Kawalec CORRESPONDENCE Open access 29 March 2013 Pages: 533 - 535
